Proportion of antifungal agent use (other than prophylactic use) · people with cancer who have febrile neutropenia
It is very uncertain whether pre‐emptive antifungal therapy changes proportion of antifungal agent use (other than prophylactic use) compared with empirical antifungal therapy (very low certainty).
1 finding from 1 review
Intervention not reported
Antibiotics prior to long‐term CVC insertion versus control: catheter‐related infections · adults and children diagnosed with an oncologic disease with a newly‐inserted long‐term CVC who were at risk of neutropenia due to…
The intervention showed no clear difference in antibiotics prior to long‐term CVC insertion versus control:… (moderate certainty).
1 finding from 1 review
Intervention not reported
Antibiotic versus heparin only lock/flush solution: catheter‐related infections · adults and children diagnosed with an oncologic disease with a newly‐inserted long‐term CVC who were at risk of neutropenia due to…
The intervention probably leads to lower antibiotic versus heparin only lock/flush solution: catheter‐related… (moderate certainty).
1 finding from 1 review
Intervention not reported
Antibiotic versus heparin only lock/flush solution: adverse events · adults and children diagnosed with an oncologic disease with a newly‐inserted long‐term CVC who were at risk of neutropenia due to…
1 finding from 1 review
Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis probably leads to lower pulmonary embolism compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in symptomatic deep vein thrombosis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in minor bleeding compared with no prophylaxis (low certainty).
1 finding from 1 review
Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes pulmonary embolism compared with no prophylaxis (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes symptomatic deep vein thrombosis compared with no prophylaxis (very low certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher minor bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Cervical cancer ‐ not measured · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Cervical cancer ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found